NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

BioInvent International AB (publ) (F: BIX)

 
BIX Technical Analysis
3
As on 20th Dec 2021 BIX STOCK Price closed @ 0.32 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.33 & Sell for SHORT-TERM with Stoploss of 0.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BIXSTOCK Price

Open 0.34 Change Price %
High 0.34 1 Day 0.00 0.00
Low 0.32 1 Week 0.00 0.00
Close 0.32 1 Month -0.06 -15.79
Volume 47200 1 Year 0.02 6.67
52 Week High 0.38 | 52 Week Low 0.30
 
F Germany Most Active Stocks
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
TOE 0.02 0.00%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
BIX
Daily Charts
BIX
Intraday Charts
Whats New @
Bazaartrend
BIX
Free Analysis
 
BIX Important Levels Intraday
RESISTANCE0.36
RESISTANCE0.35
RESISTANCE0.34
RESISTANCE0.33
SUPPORT0.31
SUPPORT0.30
SUPPORT0.29
SUPPORT0.28
 
BIX Forecast May 2024
4th UP Forecast0.42
3rd UP Forecast0.39
2nd UP Forecast0.37
1st UP Forecast0.35
1st DOWN Forecast0.29
2nd DOWN Forecast0.27
3rd DOWN Forecast0.25
4th DOWN Forecast0.22
 
BIX Weekly Forecast
4th UP Forecast0.36
3rd UP Forecast0.35
2nd UP Forecast0.34
1st UP Forecast0.33
1st DOWN Forecast0.31
2nd DOWN Forecast0.30
3rd DOWN Forecast0.29
4th DOWN Forecast0.28
 
BIX Forecast2024
4th UP Forecast0.47
3rd UP Forecast0.42
2nd UP Forecast0.39
1st UP Forecast0.36
1st DOWN Forecast0.28
2nd DOWN Forecast0.25
3rd DOWN Forecast0.22
4th DOWN Forecast0.17
 
 
BIX Other Details
Segment EQ
Market Capital 6793653.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BIX Address
BIX
 
BIX Latest News
 
Your Comments and Response on BioInvent International AB (publ)
 
BIX Business Profile
BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden. Address: The Gamma Building, Lund, Sweden, 223 70
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service